Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Open Access
- 15 January 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 6 (1), e384
- https://doi.org/10.1038/bcj.2015.112
Abstract
Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), creatinine, troponin, NT-proBNP and pre- and post-treatment echocardiograms, including ejection fraction (EF), average global longitudinal strain and compliance. Pre-treatment elevations in NT-proBNP and BP, as well as abnormal cardiac strain were common. A rise in NT-proBNP occurred frequently post-treatment often without corresponding cardiopulmonary symptoms. A rise in creatinine was common, lessened with hydration and often reversible. All patients had a normal EF pre-treatment. Five patients experienced a significant cardiac event (four decline in EF and one myocardial infarction), of which 2 (3.2%) were considered probably attributable to Cfz. None were rechallenged with Cfz. The ideal strategy for identifying patients at risk for cardiac events, and parameters by which to monitor for early toxicity have not been established; however, it appears baseline echocardiographic testing is not consistently predictive of toxicity. The toxicities observed suggest an endothelial mechanism and further clinical trials are needed to determine whether or not this represents a class effect or is Cfz specific.This publication has 18 references indexed in Scilit:
- Bortezomib-induced acute congestive heart failure: a case report and review of literatureAnnals of Hematology, 2014
- Bortezomib and heart failure: case‐report and review of the French Pharmacovigilance databaseFundamental & Clinical Pharmacology, 2013
- CarfilzomibBlood, 2013
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2012
- An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibBritish Journal of Haematology, 2012
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse EventsClinical Cancer Research, 2011
- Cardiotoxicity of the Anticancer Therapeutic Agent BortezomibThe American Journal of Pathology, 2010
- Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the ProteasomeCancer Research, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005